相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Real-world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive-disease small-cell lung cancer
Ayako Shiono et al.
CANCER MEDICINE (2023)
Prognostic impact of nutritional and inflammation-based risk scores in follicular lymphoma in the era of anti-CD20 targeted treatment strategies
Niklas Gebauer et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
Stephen Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Jonathan W. Goldman et al.
LANCET ONCOLOGY (2021)
Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer
Hisao Imai et al.
CANCER MEDICINE (2021)
SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)
M. Domine et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2020)
The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer
Eiki Ichihara et al.
LUNG CANCER (2020)
Sarcopenia and Visceral Adiposity Are Not Independent Prognostic Markers for Extensive Disease of Small-Cell Lung Cancer: A Single-Centered Retrospective Cohort Study
Seigo Minami et al.
WORLD JOURNAL OF ONCOLOGY (2020)
The Glasgow prognostic score at diagnosis is an independent predictor of survival in advanced stage classical Hodgkin lymphoma
Hanno Witte et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
Alessio Cortellini et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores
SeokJae Huh et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2019)
Body Mass Index (BMI), BMI Change, and Overall Survival in Patients With SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium
Daniel Shepshelovich et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score in Patients with Small Cell Lung Cancer Before First-Line Treatment with Etoposide and Progression-Free Survival
Xia-Bo Shen et al.
MEDICAL SCIENCE MONITOR (2019)
The Relation between Hemogram Parameters and Survival in Extensive-Stage Small Cell Lung Cancer
Abdullah Sakin et al.
ONCOLOGY RESEARCH AND TREATMENT (2019)
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET (2019)
Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study
Takayuki Shiroyama et al.
SCIENTIFIC REPORTS (2019)
Modified Glasgow Prognostic Score as a Prognostic Factor in Patients with Extensive Disease-Small-Cell Lung Cancer: A Retrospective Study in a Single Institute
Kei Sonehara et al.
CHEMOTHERAPY (2019)
Prognostic significance of cachexia score assessed by CT in male patients with small cell lung cancer
E. Y. Kim et al.
EUROPEAN JOURNAL OF CANCER CARE (2018)
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
Jennifer L. McQuade et al.
LANCET ONCOLOGY (2018)
Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer
Ryoko Suzuki et al.
RADIOTHERAPY AND ONCOLOGY (2018)
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer
Laura Mezquita et al.
JAMA ONCOLOGY (2018)
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
Mariaelena Capone et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Impact of baseline characteristics on extensive-stage SCLC patients treated with etoposide/carboplatin: A secondary analysis of a phase III study
Omar Abdel-Rahman
CLINICAL RESPIRATORY JOURNAL (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Current standards for clinical management of small cell lung cancer
Anna F. Farago et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody
Koung Jin Suh et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
Stephen J. Bagley et al.
LUNG CANCER (2017)
Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy
Ghayathri Jeyakumar et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer
Seigo Minami et al.
LUNG CANCER-TARGETS AND THERAPY (2017)
Modified glasgow prognostic score in patients with small-cell lung cancer
Koichi Kurishima et al.
MOLECULAR AND CLINICAL ONCOLOGY (2017)
Sarcopenia and inflammation are independent predictors of survival in male patients newly diagnosed with small cell lung cancer
Se-Il Go et al.
SUPPORTIVE CARE IN CANCER (2016)
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
P. F. Ferrucci et al.
ANNALS OF ONCOLOGY (2016)
Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
P. F. Ferrucci et al.
BRITISH JOURNAL OF CANCER (2015)
The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients
Seok Jin Kim et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Prognostic Significance of CT-Determined Sarcopenia in Patients with Small-Cell Lung Cancer
Eun Young Kim et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Small Cell Lung Cancer: Where Do We Go From Here?
Lauren Averett Byers et al.
CANCER (2015)
A systemic inflammation-based prognostic scores (mGPS) predicts overall survival of patients with small-cell lung cancer
Ting Zhou et al.
TUMOR BIOLOGY (2015)
Temporal trends from 1986 to 2008 in overall survival of small cell lung cancer patients
Matthew B. Schabath et al.
LUNG CANCER (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
The Modified Glasgow Prognostic Scores as a Predictor in Diffuse Large B Cell Lymphoma Treated with R-CHOP Regimen
Yundeok Kim et al.
YONSEI MEDICAL JOURNAL (2014)
The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer
Donald C. McMillan
CANCER TREATMENT REVIEWS (2013)
The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer
Graeme J. K. Guthrie et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2013)
Impact of cachexia on pharmacokinetic disposition of and clinical responses to oxycodone in cancer patients
Takafumi Naito et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Nutritional status, acute phase response and depression in metastatic lung cancer patients: correlations and association prognosis
Zoe Giannousi et al.
SUPPORTIVE CARE IN CANCER (2012)
The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study
M. J. Proctor et al.
BRITISH JOURNAL OF CANCER (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Should Patient-Rated Performance Status Affect Treatment Decisions in Advanced Lung Cancer?
Esther Dajczman et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer
Donald C. McMillan
PROCEEDINGS OF THE NUTRITION SOCIETY (2008)
Adipokines and ghrelin in gastric cancer cachexia
Mustafa Kerem et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
The relationship between an inflammation-based prognostic score (Glasgow Prognostic Score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer
D. J. F. Brown et al.
JOURNAL OF CLINICAL PATHOLOGY (2007)
Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database
Ramaswamy Govindan et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
分享论文
